We represented Contessa Health in its sale to Amedisys, Inc. (Nasdaq: AMED), a leading home health, hospice and personal care company, for $250 million in an all cash transaction. In addition, Amedisys plans to invest meaningfully in the future growth of Contessa’s business and proprietary informatics platform, CareConvergence™. Upon the closing of the deal, Nashville, Tennessee-based Contessa began operating as a wholly owned division of Amedisys.
The team was led by Angela Humphreys, Chair of the firm’s Healthcare Practice, and corporate partner Price Wilson and included attorneys Meredith Collins and Ali Gallagher; Elizabeth Warren (healthcare regulatory); Bryan Metcalf (tax and executive compensation); Curtis Fisher (employee benefits); and Luke Smith (antitrust).
To read the full press release of the transaction by Amedisys, click here. The transaction was highlighted in several media outlets, including:
- “With Contessa Deal Finalized, Amedisys Ready to Explore ‘New Frontier’ of Home-Based Care,” Home Health Care News (August 5, 2021)
- “Amedisys paying $250M for Contessa,” Nashville Post (July 1, 2021)
- “Amedisys’ (AMED) Contessa Buyout to Boost Home Health Business,” Yahoo! Finance (July 2, 2021)
- “Amedisys Acquires Contessa Health in $250 Million Deal,” Hospice News (June 30, 2021)
Based in Nashville Tenn., Contessa is the leader and pioneer of Home Recovery Care, a risk-based model that combines all the essential elements of inpatient hospital care and SNF at Home in the comfort of patients’ homes. Founded in 2015, Contessa utilizes CareConvergence™ – a proprietary technology platform – to coordinate and power the seamless delivery of Home Care that is safe, affordable and improves patient outcomes. Contessa’s turnkey solution provides upfront savings to health plans, enables health systems to reinvent their care delivery model and helps physicians deliver a better experience for their patients.
This transaction was named a a finalist in the following categories for the 21st Annual M&A Advisor Awards in 2022:
- Healthcare/Life Sciences Deal of the Year (Between $100MM-$500MM)
- Corporate/Strategic Deal of the Year (Between $250MM-$500MM)
- M&A Deal of the Year (Between $250MM-$500MM)
Bass, Berry & Sims was recognized as a finalist 15 times among several different categories representing six separate transactions for the 2022 Awards.
About the Bass, Berry & Sims Healthcare Practice
Marked by an integrated approach and unmatched regulatory knowledge, the healthcare practice of Bass, Berry & Sims is a team of more than 230 experienced attorneys who leverages their diverse strengths to meet the unique demands of our clients. Our team encompasses the multitude of legal specialties necessary to service one of the largest, most highly regulated industries in the U.S. The firm has been recognized by leading healthcare and legal industry outlets, including, nationally ranked by Chambers USA for the last six years (2016-2021), recognized as the third largest healthcare law firm in the U.S. by the American Health Law Association (2021), and honored in the healthcare category as a Law360 Practice Group of the Year (2020). Read more here.